Augmenting neurocognitive remediation therapy to Preventive Cognitive Therapy for partially remitted depressed patients: protocol of a pragmatic multicentre randomised controlled trial
Introduction Major depressive disorder (MDD) affects 163 million people globally every year. Individuals who experience subsyndromal depressive symptoms during remission (ie, partial remission of MDD) are especially at risk for a return to a depressive episode within an average of 4 months. Simultan...
Saved in:
Main Authors: | Huibert Burger, Claudi Bockting, Marlies Brouwer, Gert J Geurtsen, Amanda M Legemaat, Johanne G J van der Stappen, Maria Semkovska, Isidoor O Bergfeld, Nicoline Lous, Damiaan A J P Denys |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-06-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/6/e063407.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatments for partial remission of major depressive disorder: a systematic review and meta-analysis
by: Marlies E Brouwer, et al.
Published: (2023-11-01) -
Comorbidity in in patients with relapsing-remitting multiple sclerosis
by: O.V. Somilo, et al.
Published: (2024-10-01) -
Neurological and neurocognitive alterations by COVID-19
by: Charles Ysaacc Da Silva Rodrigues
Published: (2020-12-01) -
Is Valproate Depressogenic in Patients Remitting from Acute Mania? Case Series
by: Kamini Vasudev, et al.
Published: (2015-01-01) -
FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis
by: David Hunt, et al.
Published: (2022-06-01)